NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on this topic.
- Other notable experts such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Naval G. Daver, MD, contribute to the discussion.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Additional experts like Anne Chiang, MD, PhD, J. Douglas Miles, MD, PhD, FAAN, and Zev A. Shah, MD, FASCO, also provide their perspectives.
Author's summary: NGS enhances biomarker testing for solid tumors.
More News
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Fraternity and hope strengthen relations between Catholics and Anglicans
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- [Event] 15th Annual New York Forum on Economic Sanctions - December 3rd - 4th, New York, NY | JD Supra
- Anglicans need more than one boat - THE OTHER CHEEK
- Kentucky families fear losing SNAP benefits in November as government shutdown drags on
- Praia Health’s Kurt Hammond on Powering Providence’s Work With Labcorp
- Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec
- High-speed motorcycle chase ends in violent crash on Southern California freeway
- Why the Informal Sector Is Not a Tax Goldmine - Institute of Development Studies